| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2008 | WO2008029282A3 Aqueous formulation comprising an antitumor agent |
| 05/22/2008 | WO2008028805A3 Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections |
| 05/22/2008 | WO2008024734A3 Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| 05/22/2008 | WO2008023004A8 Single enantiomer beta agonists method for production and use thereof as a medicament |
| 05/22/2008 | WO2008023003A8 Drug combinations for treating airway diseases |
| 05/22/2008 | WO2008022024A3 Imidazole amines as inhibitors of beta-secretase |
| 05/22/2008 | WO2008021550A3 Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents |
| 05/22/2008 | WO2008021364A8 Triazole compounds that modulate hsp90 activity |
| 05/22/2008 | WO2008021331A3 Oxazolidone derivatives as pr modulators |
| 05/22/2008 | WO2008018783B1 Porphyrin activation by different spectrum electromagnetical waves-new malignant tumour treatment possibilities |
| 05/22/2008 | WO2008017521A3 Compositions with enhanced elasticizing activity |
| 05/22/2008 | WO2008012413A3 Pyrimidinone derivatives and their use as a drug |
| 05/22/2008 | WO2008011392A3 Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation |
| 05/22/2008 | WO2008008364A3 Enhanced stability phenylephrine liquid compositions |
| 05/22/2008 | WO2008006974A3 Use of histamine h4 receptor ligands to protect haematopoietic progenitors against the haematological toxicity of chemotherapeutic agents |
| 05/22/2008 | WO2008005266A3 Method of using substituted piperidines that increase p53 activity |
| 05/22/2008 | WO2008003149A3 Substituted pteridines for the treatment and prevention of viral infections |
| 05/22/2008 | WO2008000421A3 Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors |
| 05/22/2008 | WO2007147770A3 Substituted phenyl methanone derivatives |
| 05/22/2008 | WO2007144169A3 Entacapone-derivatives |
| 05/22/2008 | WO2007139778A3 Rhamnose substituents of sl0101 and therapeutic uses thereof |
| 05/22/2008 | WO2007138531A3 Treatment of erectile dysfunction and libido enhancement |
| 05/22/2008 | WO2007138431A3 Azabicyclic ether histamine-3 antagonists |
| 05/22/2008 | WO2007133583A3 Zero-order modified release solid dosage forms |
| 05/22/2008 | WO2007132296B1 Multilayer tablet |
| 05/22/2008 | WO2007132175A3 Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer |
| 05/22/2008 | WO2007130824A3 Fused heterocylic compounds and their use as mglur5 modulators |
| 05/22/2008 | WO2007128477A3 SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION |
| 05/22/2008 | WO2007127725A3 Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods |
| 05/22/2008 | WO2007127010A9 Diarylthiohydantoin compounds |
| 05/22/2008 | WO2007124252A3 Combinations of therapeutic agents for treating cancer |
| 05/22/2008 | WO2007121481A3 Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
| 05/22/2008 | WO2007120702A3 Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
| 05/22/2008 | WO2007119249A3 Pharmaceutical compositions of cefixime |
| 05/22/2008 | WO2007108010A3 Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate |
| 05/22/2008 | WO2007104557A3 Novel heterocyclic nf-kb inhibitors |
| 05/22/2008 | WO2007100560A3 Use of dha and ara in the preparation of a composition for inducing the expression of pulmonary surfactant protein-b |
| 05/22/2008 | WO2007100435A3 Use of dha and ara in the preparation of a composition for the prevention or treatment of anemia |
| 05/22/2008 | WO2007070430A3 Identification and application of antibiotic synergy |
| 05/22/2008 | WO2007047486A3 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| 05/22/2008 | WO2006055561A3 Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| 05/22/2008 | WO2006005611A3 Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents |
| 05/22/2008 | US20080120734 Compositions and methods for regulated protein expression in gut |
| 05/22/2008 | US20080119859 Multi-Purpose Bio-Material Composition |
| 05/22/2008 | US20080119820 Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief |
| 05/22/2008 | US20080119781 Method and apparatus for treating scar tissue |
| 05/22/2008 | US20080119649 Halocombstatins and methods of synthesis thereof |
| 05/22/2008 | US20080119572 Treatment for basal cell carcinoma |
| 05/22/2008 | US20080119569 Polymer-based sustained release device |
| 05/22/2008 | US20080119567 Geranium oil and extracts from roots of Sophora; H. pylori infection; citronellol; sodium/potassium ATPase inhibitors; cardiovascular disorders; gastric ulcers |
| 05/22/2008 | US20080119566 Sedatives; oxidation resistance; nervous system disorders |
| 05/22/2008 | US20080119565 Novel compounds from antrodia camphorata |
| 05/22/2008 | US20080119564 evalbuterol L-hemitartrate, a crystal form; administered using a metered dose inhaler containg an aerosol in crystal form to effect bronchodilation; reproducible; stablility; storage stability; aerodynamically favorable shape, such as a fiber, to reach lung depth; antiagglomerants |
| 05/22/2008 | US20080119563 Tetraalkyl ammonium fluoride derivatives or a pyridine hydrogen fluoride complex to remove silyl protecting groups in oligoribonucleotides synthesis in less than two hours under mild conditions; the reagents can be used before the oligonucleotide is removed from the support |
| 05/22/2008 | US20080119562 Methods of Inducing Terminal Differentiation |
| 05/22/2008 | US20080119561 Methods for preventing or delaying catheter- based resvascularization |
| 05/22/2008 | US20080119560 Use treating glaucoma, ocular hypertension, or baldness; prostaglandin EP2 selective agonists are 1-hydroxy-3-chloro-4-carboxylalk(en)yl-5-(aryloxyalkyl)cyclopentanes |
| 05/22/2008 | US20080119559 Treatment or prevention of cancer and precancerous disorders |
| 05/22/2008 | US20080119558 Drug for Inhibiting Production of Matrix Metalloprotease-9 |
| 05/22/2008 | US20080119557 A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders |
| 05/22/2008 | US20080119556 Geranly compounds |
| 05/22/2008 | US20080119555 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions |
| 05/22/2008 | US20080119554 Compositions Comprising Ornithine And Phenylacetate Or Phenylbutyrate For Treating Hepatic Encephalopathy |
| 05/22/2008 | US20080119553 Preventive and/or therapeutic treatment of hyperlipidemia or non-insulin dependent diabetes mellitus which comprises dministering orally a polyprenyl compound 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (NIK-333); antidiabetic and -lipemic agents |
| 05/22/2008 | US20080119552 Matrix-embedded compositions having organic acids and fatty acids |
| 05/22/2008 | US20080119551 Skin cosmetics comprising a cystine derivative and a chemical peeling agent, a bactericide, an anionic sufactant, or a cationic surfactant |
| 05/22/2008 | US20080119550 Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection |
| 05/22/2008 | US20080119549 Phenyl esters of alkylcarbamic acids; analgesics |
| 05/22/2008 | US20080119548 Control Of Feeding Behavior By Changing Neuronal Energy Balance |
| 05/22/2008 | US20080119547 Treating of a psychological disorder by administering a 3-Benzo[1,3]dioxol-5-yl-indan-1-yl)-dimethylamine or analogous 1,3-dithio, 1-oxa-3-thio ring derivatives; antidepressants; anxiolytic agents; post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, phobias |
| 05/22/2008 | US20080119546 Treatment of hyperproliferative conditions of body surfaces |
| 05/22/2008 | US20080119545 Method for preventing and treating avian influenza in human |
| 05/22/2008 | US20080119544 Use for Cannabinoid |
| 05/22/2008 | US20080119543 Method of purifying moxidectin through crystallization |
| 05/22/2008 | US20080119542 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| 05/22/2008 | US20080119541 Novel genes encoding a nystatin polyketide synthase and their manipulation and utility |
| 05/22/2008 | US20080119540 Ingesting daily a compound of tetrahydrolipstatin (Orlistat) for a period of at least two years to prevent weight regain; long-term therapy so as to permanently atrophy the endocrine cells which would otherwise generate more ghrelin; appetite reduction |
| 05/22/2008 | US20080119539 Therapeutic amides |
| 05/22/2008 | US20080119538 Therapeutic compounds |
| 05/22/2008 | US20080119537 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators |
| 05/22/2008 | US20080119535 Aminomethyl-4-imidazoles |
| 05/22/2008 | US20080119534 Benzimidazole Derivatives as Therapeutic Agents |
| 05/22/2008 | US20080119533 New class of antibiotic with potent antibacterial activity against even methicillin resistant Staphylcoccus aureus (MRSA); 3-methylthio-4-phenyl-5-methoxyacetyl-oxazolidin-2-one for example |
| 05/22/2008 | US20080119532 2-Methylamino-N-{2-(6-{1-methyl-2-(2-methylamino-propionylamino)-3-oxo-3-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-yl]-propoxy}-hexa-2,4-diynyloxy)-1-[2-(5-phenoxy-tetrazol-1-ylmethyl)-pyrrolidine-1-carbonyl]-propyl}-propionamide; mimetics of second mitochondria-derived activator of caspases |
| 05/22/2008 | US20080119531 PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent |
| 05/22/2008 | US20080119530 Topically administrating an inhibitor of Erbb2 or HER2 receptor tyrosine kinase activity because of a novel connection between HER2 and a DNA damage checkpoint; reducing mutagenesis and apoptosis; antitumor, -carcinogenic, -proliferative agents and -inflammatory agents; sunburn; hyperplasia |
| 05/22/2008 | US20080119529 An epothilone derivative such as epothilone A,B,C or D with a bisphosphonate such as zoledronic acid, a platinum compound such as carboplatin or a vasculostatic compound such as vatalanib succinate; antitumor agents |
| 05/22/2008 | US20080119528 use of specific cyklolignans |
| 05/22/2008 | US20080119527 Composition for combating the localized hyperpigmentation of dark skin |
| 05/22/2008 | US20080119526 Ep2 receptor agonists |
| 05/22/2008 | US20080119525 Pyridoxamine for the Treatment of Diabetic Intermediaries and Post-Amadori Inhibition |
| 05/22/2008 | US20080119524 Treating conditions related to Ras or Ras-like protein prenylation such as cancer, restenosis, psoriasis, endometriosis, atherosclerosis, ischemia, myocardial ischemic disorders; amide-functional pyrazole compounds containing 2,2-dimethylcyclobutan-1,3-ylene moiety |
| 05/22/2008 | US20080119523 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1h-benzimidazol-5- carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
| 05/22/2008 | US20080119522 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer |
| 05/22/2008 | US20080119521 Butyrlcholinesterase Selective Inhibitors |
| 05/22/2008 | US20080119520 Disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight; benzoxazole, benzimidazole, and indole compounds substituted with pyrrole, azepane, piperidine or azetidine e.g. 4-{2-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-benzooxazol-5-yl}-benzonitrile |
| 05/22/2008 | US20080119519 Base Forming Drug-Layered Silicate Hybrid Containing Basic Polymer and its Synthesis Method |
| 05/22/2008 | US20080119518 Indole-6-carboxamides; for example 1-[1-[2-(2-methoxy-4-methoxymethylphenyl)ethyl]piperidin-4-yl]-1H-indole-6-carboxamide; treating frequent urination and incontinence; 5-HT1A receptor antagonists |
| 05/22/2008 | US20080119517 Compositions and methods for protecting against mitochondria component-mediated pathology |
| 05/22/2008 | US20080119516 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity |